Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-16T07:28:57.292Z Has data issue: false hasContentIssue false
  • English
  • Français

Prolonged High Dosage Ataractic Medication in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

D. Rosati
D. Rosati*
Affiliation:
Veterans Administration Hospital, Leech Farm Road, Pittsburgh 6, Pennsylvania
Get access Rights & Permissions [Opens in a new window]

Extract

Ataractic drugs have been the mainstay of treatment in schizophrenia for the last eight years. Since their introduction, mental hospitals, in various areas of the United States and in every country, have been able to discharge more patients than they admit. Despite this fact there remains much divergent opinion about the value of these drugs, doubt arising from inconsistent therapeutic results and the relapse rate. Also, some double-blind studies have cast some doubt upon the efficiency of these drugs. We are reporting this relatively small study because we feel that it opens an insight and possibly suggests a method of standardizing treatment in the near future.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 110 , Issue 464 , January 1964 , pp. 61 - 63
Copyright
Copyright © Royal College of Psychiatrists, 1964 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lotus, T. A., et al. (1961). “Negative results with Prochlorpromazine and benactyzine in a group of chronic patients” Psychiat. Quart., 35 (1).Google Scholar
Tuteur, V., Stiller, R., and Glotzer, J. (1958). “Results with chlorpromazine on chronically nude. incontinent, combative and noisy patients” Dis, New. Syst., 19, (8), 339.Google Scholar
Rosen, I. (1960). “Appraisal of milieu therapy” Dis. Nerv. Syst.; or Transactions of Fifth Research Conference on Co-operative Chemotherapy Studies in Psychiatry, 1959. Volume 5. Veterans Administration.Google Scholar
Goldman, D. (1958). “Effects of prochlorpromazine on psychotic patients” Psychiatric Research Reports. Google Scholar
Kline, N. (1958). “The use of prochlorpromazine in a variety of psychiatric conditions” Ibid. Google Scholar
Gross, , Martin, (1960). “The impact of ataractic drugs in a mental hospital out-patient clinic” Transactions of Fifth Research Conference on Co-operative Chemotherapy Studies in Psychiatry, 1959. Volume 5. Veterans Administration.Google Scholar
Kramer, M., Goldstein, H., Israel, R. H., and Johnson, N. A. (1955). “A historical study of the disposition of first admissions to a state mental hospital” Public Health Monograph, 32.Google Scholar
Judah, L. N., Josephs, Z. M., and Murphree, O. D. (1961). “Results of simultaneous abrupt withdrawal of ataractic drugs in 500 chronic psychotic patients” Amer. J. Psychiat., 118, 156.Google Scholar
Good, W., et al. (1958). “Termination of prochlorpromazine with schizophrenic patients” Chemotherapy in Psychiatry. Veterans Administration.Google Scholar
Margolis, Lester (1957). “Pharmacotherapy in psychiatry” Ann. N.T. Acad. Sci., 66.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.